Lataa...
Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting
Since the approval of sorafenib, an inhibitor of vascular endothelial growth factor receptor (VEGFR), in December 2005, seven drugs have been introduced that have provided a high level of clinical efficacy in patients with mRCC, with a median survival ~30 months in an unselected patient population t...
Tallennettuna:
| Julkaisussa: | Urol Oncol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4654640/ https://ncbi.nlm.nih.gov/pubmed/26482392 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2015.08.007 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|